Everolimus efficacy across adult age ranges


  • Everolimus (EVE) as an add-on therapy mitigates seizure frequency for individuals with tuberous sclerosis complex (TSC) epilepsy, with no reduction in efficacy due to a person’s age.

Why this matters

    While preclinical data indicates the effectiveness of EVE in treating TSC epilepsy may vary by age, there is a lack of published data about EVE on older adults in a clinical setting.